Niagen Bioscience, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $129.4M | $99.6M | $83.6M | $72.0M | $67.4M |
| Cost of revenue | $46.2M | $38.0M | $32.8M | $29.3M | $26.0M |
| Gross profit | $83.2M | $61.6M | $50.8M | $42.8M | $41.5M |
| Research and development | $6.3M | $6.0M | $5.0M | $4.8M | $3.8M |
| Operating expenses | $66.9M | $53.9M | $56.4M | $61.4M | $68.6M |
| Operating income | $16.3M | $7.7M | -$5.6M | -$18.6M | -$27.1M |
| Interest expense | — | — | — | — | $55,000 |
| Pretax income | $18.2M | $8.9M | -$4.9M | — | — |
| Income tax expense | $810,000 | $305,000 | $0 | — | — |
| Net income | $17.4M | $8.6M | -$4.9M | -$16.5M | -$27.1M |
| Balance Sheet | |||||
| Cash and equivalents | — | $44.5M | $27.2M | $20.3M | $28.2M |
| Current assets | $96.8M | $64.1M | $49.5M | $46.6M | $48.9M |
| Total assets | $106.4M | $68.3M | $55.0M | $54.1M | $57.8M |
| Current liabilities | $19.9M | $17.9M | $20.6M | $17.9M | $17.6M |
| Total liabilities | $29.9M | $22.2M | $26.5M | $25.4M | $26.1M |
| Stockholders' equity | $76.5M | $46.1M | $28.5M | $28.7M | $31.7M |
| Cash Flow Statement | |||||
| Cash from operations | $13.5M | $12.1M | $7.1M | -$15.1M | -$24.2M |
| Depreciation and amortization | $612,000 | $663,000 | $870,000 | $869,000 | $890,000 |
| Stock-based compensation | $6.1M | $3.7M | $4.8M | $5.7M | $6.2M |
| Share repurchases | $251,000 | $0 | — | — | — |
| Impairments | $0 | $0 | $3,000 | $0 | $0 |
Shares outstanding 79.6M · Free float 22.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.